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Abstract
Bacteria express beta-lactamases to counteract the beneficial action of antibiotics. Benzo[b]-thiophene-2-boronic acid (BZB)
derivatives are b-lactamase inhibitors and, as such, promising compounds to be associated with b-lactam antibacterial
therapies. The uncharged form of BZB, in particular, is suggested to diffuse through the outer membrane of Gram negative
bacteria. In this study, through the combination of electrophysiological experiments across reconstituted PC/n-decane
bilayers and metadynamics-based free energy calculations, we investigate the permeation mechanism of boronic
compounds. Our experimental data establish that BZB passes through the membrane, while computer simulations provide
hints for the existence of an aqueous, water-filled monomolecular channel. These findings provide new perspectives for the
design of boronic acid derivatives with high membrane permeability.
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Introduction
The onset of Gram-negative bacteria’s resistance to b-lactam
antibiotics is a major threat to public health [1]. The widespread
use of this compound class caused the development of resistance
mechanisms that make these drugs ineffective. There are different
resistance mechanisms to counteract the activity of b-lactam
antibiotics. One of them is the expression of b-lactamase (bLs),
enzymes that catalyze the hydrolysis of the b-lactam ring of the
antibiotic, destroying hereby their antibacterial activity [2,3,4].
Inhibitors structurally similar to these antibiotics, featuring the b-
lactam ring, have been developed to block the bLs action. The
broad activity of class C b-Ls and the regulatory response to classic
b-lactams motivated the search for novel inhibitors structurally
unrelated to b-lactams. Non-b-lactam inhibitors are able to evade
pre-evolved bacterial resistance mechanism: they are not recog-
nized by b-lactam signalling proteins, are not affected by porin
channel mutations responsible for decreasing permeability, and,
lacking the b-lactam core, they should not be hydrolyzed by
mutant enzymes that arise in response to new b-lactams [5,6,7,8].
Among those, benzo[b]-thiophene-2-boronic acid (BZB, Fig. 1) is
one of the highest potent b-lactamase inhibitor boronic com-
pounds in vitro (Ki=27 nM towards ampicillin resistant class C b-
lactamase, AmpC) [8,9,10,11,12,13]. Despite its tight binding and
ligand efficacy, BZB showed only modest celluar activity and when
administered in combination with third generation cephalosporins
like ceftazidime (CAZa), it was only active in the tens-of-
micromolar range in antimicrobial cell-based assays, a thousand-
fold worse than its Ki value [10,14,15,16]. Such low in vivo
efficiency is likely to be related to inefficient membrane
permeation. Experiments in which polymixine was used to
disaggregate the membrane showed an higher amount of
compound entering the cells, inducing significant minimum
inhibitory concentration amelioration: the efficiency observed
was then closer to the effective Ki versus the enzyme. More
recently, Venturelli et al. have identified 5-aminomethylben-
zo[b]thiophen-2-boronic acid (BZD) as a BZB’s derivative with an
improved permeability index (PI) [10] and better cell efficacy
despite its higher Ki (260 nM) [10,14].
Our previous studies on BZD [15,16] focused on its passage
through the outer membrane via porin channels, the same route
supposed for b-lactams themselves. At variance, BZB is supposed
to diffuse passively through the outer membrane: for this series of
inhibitors, structural variations strongly influence the route to cell
entry. The low efficiency of BZB is caused most probably by an
excess of the negatively charged form (about 90%) due to the pKa
value of the boronic group (pKa=6.39) at physiological pH [17].
Figure 1. bLs boronic inhibitors. BZB benzo[b]thiophene-2-boronic
acid, BZD 5-aminomethyl benzo[b]thiophene-2-boronic acid.
doi:10.1371/journal.pone.0023187.g001
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with very low efficiency, since the membrane is lipophilic. The less
abundant neutral form is expected to pass more efficiently and is
probably responsible for the antimicrobial activity as observed for
other b-lactam antibiotics [17]. This effect has never been studied
for the boronic compound class. A deeper investigation of the
permeation process aimed at understanding how structural
features of compounds may influence membrane crossing, may
provide useful hints to the design of novel boron-based drugs with
improved permeability efficiency [18,19]. Here we address this
issue through a combination of electrophysiological experiments
and atomistic simulations. Experiments with reconstituted mem-
branes, made of PC/n-decane, were carried out using BZB and
BZD for comparison in the presence or absence of OmpF porins,
at different pH values. The dependence of the electrophysiological
behavior on pH is consistent with the fact that the percentage of
the neutral and negatively charged forms (Fig. 2) changes
significantly. In particular, the negative form passes from 90% at
pH=7.35 to 29% at pH=6.
Electrophysiological experiments were carried out on BZD that,
differently from BZB, was expected to cross the membrane
through membrane porins that are permeable to cationic
antibiotics. The pKa of the boronic group is the same as for
BZB (pKa=6.39) [14] while the amino group (pKa=9.26) [14] is
positively charged at physiological pH, therefore it represents the
optimal compound for comparison with BZB in our experimental
conditions.
While a model of the membrane translocation of negatively
charged antibiotics and low water soluble compounds has already
been proposed [20], the model for the translocation of boronic
acid derivatives across bacterial membranes is still a matter of
debate. Here, we present a model that is consistent with the
experimental data, by performing atomistic molecular dynamics
simulations to investigate the permeation of BZB through the
bacterial membrane, modeled as a POPC bilayer. Since the
transport mechanism is very likely to be associated with a high
activation barrier, we used the metadynamics method [21,22] to
evaluate the free energy profile for the translocation of the
compound through the membrane. This technique has been
widely tested and used in a variety of biophysical applications [22],
including permeation of antibiotics through porins [23,24,25].
Results and Discussion
To establish the membrane permeation mechanism of the BZB
at physiological pH (pH=7.35), our investigation proceeded in
several steps. First, we used electrophysiological methods to assess
whether BZB passes through the membrane, through membrane
porins or through both and which form of BZB, negatively
charged or neutral, could cross the membrane. Then, we used
metadynamics simulations to investigate the molecular determi-
nants of the permeation process.
We measured the single-channel conductance (SCC) of lipid
bilayer membranes made of PC/n-decane in the presence of
OmpF porins, in unbuffered 1 M KCl (pH is about 6) with or
without BZB. At this pH, BZB is present as 71% in neutral form
and 29% in negatively charged form. The negative form of BZB
cannot pass through OmpF porins because these proteins are
selective for cations and tend to block also in vivo transport of
negatively charged bile acids into the bacteria [26]. On the other
hand, OmpF porins are known to let hydrophilic antibiotics pass
[7,27]. If BZB permeates, at least in part, through the porins, the
SCC must decrease upon addition of BZB [28,29]. In our
experiments the SCC of the same system plus 0.5 mM BZB on
both sides of the membrane was 4.1 nS, very similar to the SCC of
the membrane alone [26,30] (see Text S1 for details). The same
result was also obtained with a larger number of OmpF pores
reconstituted into the membranes (OmpF concentration 20 ng/
mL) and with further additions of 0.15 mM BZB on both sides of
the membrane (increasing BZB concentration from 1 to 2.9 mM).
The results for single- and multi-channel experiments thus clearly
indicate that BZB translocation does not depend on porins and is a
process that takes place exclusively through the membrane.
Similar experiments were also performed with BZD. Interest-
ingly, we observed in single-channel experiments a small but
significant decrease of conductance presumably because the bulky
BZD could enter the porin channel thus hindering the flux of ions
through the channel. Figure 3 shows histograms of the single
channel conductance distributions in absence (Fig. 3A) and in
presence of BZD (Fig. 3B). The single channel conductance of
OmpF decreased from an average 4.1 nS (Fig. 3A) to 3.4 nS
(Fig. 3B) when 0.45 mM BZD was added to the aqueous phase.
Similar effects on porin conductance have also been observed in
previous studies with other compounds including antibiotics
[28,29].
In subsequent experiments (data not shown), a large number of
OmpF pores were reconstituted into lipid bilayer membranes.
Then BZD was added to the aqueous phase on both sides of the
membrane in increasing concentrations starting from 0.15 mM.
The addition of BZD resulted in a further decrease of membrane
conductance caused by the same effect as described above for the
single-channel measurements. Hence we conclude that BZD is
able to enter the OmpF pores and to block in part the current
through the OmpF channels.
In a second step, we investigated the permeation of BZB
through a PC/n-decane membrane. We measured the membrane
conductance at physiological pH (pH 7.35) in which 90% of BZB
is present in its negative form and only 10% in its neutral form.
When increasing concentrations of BZB were added to both sides
of the membrane starting from 0.15 mM up to 2.9 mM, we
observed transient increases of membrane conductance following
each BZB addition (see Fig. 4).
The current through unmodified lipid bilayer membranes is
normally very low because these membranes have a resistance of
about 100 GV (diameter 0.5 mm) in the absence of membrane-
active substances. The addition of the charged BZB compounds
increased the conductance of the membrane (current transient)
because the compound acts like a lipophilic ion due to charge
Figure 2. BZB reversible adducts formed with water hydroxyl, resembling the high energy intermediate of enzyme reaction.
doi:10.1371/journal.pone.0023187.g002
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Lipophilic ions move through the membrane [17] with low
efficiency and hence very slowly in comparison to neutral
compounds. The current transient is caused by slow aqueous
diffusion of the negatively charged BZB compound that moves
faster through the membrane than through the aqueous phase
(unstirred layers) at the membrane-water interface causing
diffusion polarisation [17]. The neutral compound contributed
to this process. Polar compounds tend to decrease the dipole
potential of membranes when they are adsorbed in a direction that
is perpendicular to the existing dipole potential. A typical such
molecule is phloretin [31]. However this effect is difficult to
measure. Although we conclude that both the negative and neutral
forms of BZB pass through the lipid bilayer membranes, the
neutral, more hydrophobic, form moves faster: as a consequence
this form is transported through the membrane more efficiently
and is therefore responsible for the biological activity, that is low
given the low fraction of neutral form present.
Since the neutral form is responsible for the biological activity
and permeates through the membrane, we focused our compu-
tational studies on the translocation mechanism of this form. The
free energy and the molecular mechanism of the process were
reconstructed by metadynamics calculations [21,22]. The resulting
converged free energy profile G(z) is symmetric with respect to the
central plane of the membrane, as expected (Fig. 5). It increases
from the water phase into the hydrophobic core. The resulting
activation free energy barrier is DG
#=6368 KJ/mol. This result
may be used to calculate the permeability coefficient (See Text S1
for details), which can be compared with the related experimental
quantity. The latter has been measured for b-lactam antibiotics
across the bacterial membrane [32] and for boric acids across
membrane vesicles [33]. We calculated a value of permeability
coefficient ranging from 7610
29 to 8610
212 cm/s. The upper
value is in the range of experimental values measured with other
systems [18]. Using the Arrhenius formula the barrier may also be
associated to a timescale ranging from 10
23 s to 3 s. Further
experiments are required to test the validity of these predictions.
The inspection of the permeation mechanism clearly shows that
the B-(OH)2 moiety H-bonds to one or more water molecules
upon leaving the membrane surface: this is clearly shown by the B-
(OH)2 –water coordination numbers (Fig. 6) as well as visual
inspection of representative metadynamics snapshots (Fig. 5). The
water molecule is connected to other water molecules in a chain-
Figure 3. Histogram of the probability P(G) for the occurrence
of a given conductivity unit. Probability observed with lipid bilayer
membranes in the presence of OmpF alone (A) or when the aqueous
phase contained in addition 0.45 mM BZD (B). P(G) is the probability
that a given conductance increment G is observed in the single-channel
experiments calculated as reported in Fig. S1.
doi:10.1371/journal.pone.0023187.g003
Figure 4. Recording of PC/n-decane membrane conductance measured at pH 7.35 after addition of BZB in increasing
concentrations from 1.0 mM to 2.9 mM.
doi:10.1371/journal.pone.0023187.g004
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channel connecting BZB with side A starts to break.
Drug permeation causes some rearrangement of the membrane
surface. The calculated dipole of BZB (m) is 2.85 Debye. It points
towards the B-(OH)2 group (Fig. 6, bottom). The H angle between
m and the z direction is as small as 35u inside the membrane (Fig. 6,
bottom) where the compound tends to align with the lipids tails.
This has been observed for similar drugs [18,34]. Instead H
increases up to 60u, when the drug is in contact with the solvent,
possibly because of the formation of H-bonds with the charged
groups of the phospholipids as well as with water molecules. This is
the molecular rationale for the observed behaviour that polar
molecules tend to decrease the dipole potential of the membrane
being absorbed in a direction that is perpendicular to the existing
membrane dipole.
In this work, we have reported a combined experimental and
computational study on the permeation of BZB through model
membranes. Our experiments establish that BZB passes through
the membrane both in charged and neutral form, as it was
proposed in our previous work, where the neutral form, more
lipophilic, is known to move faster (Fig. 1); the translocation of
neutral BZB occurs via permeation though the membrane and is
not assisted by porins. In our model the neutral BZB translocates
assisted by a water channel bound to the boronic group. The
neutral form is present in much smaller concentration than the
negative one (about 10%) at pH 7.35. For comparison, the
positively charged BZD compound (5-aminometil-BZB) with
lower pKa, displays higher antibacterial activity and is shown to
cross the membrane through porin channels. In this work, we have
obtained more insights on the structural and energetic features
associated with the permeation of BZB in the neutral form through
the membrane via molecular dynamics simulations. Our calcula-
tions provide a permeability coefficient similar to that found for
some antibiotics [32] and characterized by a translocation time
ranging from 10
23 s to 3 s; they suggest that the hydrophilic part
of the molecule is partially hydrated during the whole permeation
process. In particular, a monomolecular water channel assists
translocation, the BZB dipole tends to align to the lipid tails inside
the membrane and, as a consequence, contribute to the overall
SCC transient signal observed in our experiments.
This study provides mechanistic insight on how the efficient
permeation of boronic derivatives affects antibacterial activity.
Medicinal chemistry usually adopts weak positively charged
groups to increase the membrane permeability of candidate drugs
that easily pass through the porins, as in the case of BZD and other
positively charged derivatives. In this case, however, the option of
a porin mutation is available and bacteria might develop a rapid
resistance to these drugs. This resistance mechanism can be
overcome by employing molecules that permeate directly through
the bacterial membrane, as BZB derivatives. Unfortunately,
however, membrane permeation can be slow and this decreases
the antibacterial activity potential. Here we provide information
on the structural determinants of BZB permeation through the
membrane by molecular simulations. Our calculations show that a
Figure 5. (Left) Representative snapshots of BZB permeation as obtained by metadynamics. The water channel accompanying BZB
translocation is shown in ball and sticks at selected positions of the drug. The P and N atoms of POPC are displayed as orange and blue spheres,
respectively. The whole POPC molecules are represented as lines in the first and last frame. (Right) G(z) calculated as a function of z-dist. G(z) is
obtained as the average of 5 independent profiles. The mean value of the averaged FES within the four-region scheme is represented by red stars
(see Text S1 for more details).
doi:10.1371/journal.pone.0023187.g005
Figure 6. Dipole moment. Top: Coordination number of the O1 and
O2 atoms of BZB with the water oxygens (O(wat), top) and POPC
phosphate oxygens, (O(POPC), middle). Bottom: the angle Q between
the dipole moment of the drug m and the z-axis as a function of z-dist.
doi:10.1371/journal.pone.0023187.g006
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observations could be used for chemical modifications of BZB to
obtain compounds with improved membrane permeability.
Materials and Methods
Lipid bilayer experiments
BZB was provided by Sigma, BZD was synthesized using a
previously published method [15,16]. The methods used for the
lipid bilayer experiments and the isolation of OmpF porin from
Escherichia coli K12 have been described previously [26,30]. In
experiments with OmpF alone the membranes were formed from
diphytanoyl phosphatidylcholine/n-decane and the aqueous phase
contained 20 ng/ml of purified OmpF of E. coli K12 and 1 M
KCl. The most frequent single channel conductance (about 58%)
was 4.0 nS for 108 single channel events. The applied membrane
potential was 20 mV; T=20uC. The final data were calculated
from measurements from 5 individual membranes. Experiments
with BZD were conducted in the same conditions, but the aqueous
phase contained in addition 0.45 mM BZD. Most frequent single-
channel conductance was 3.5 nS for in total 104 single-channel
events. The data were collected from more than 5 individual
membranes. The aqueous phase contained 20 ng/ml OmpF, 1 M
KCl and 0.45 mM BZD.
Molecular Simulations
A5 0A ˚650 A ˚ POPC bilayer patch resulting in 60 1-palmitoyl-
2-oleoyl-phosphatidylcholine (POPC) lipid molecules, was filled
with TIP3P water molecules. The resulting system consisted of
16432 atoms. We reproduce some of the previously calculated
properties, thus ensuring the validity of our parameterization (see
Text S1). Then we added the BZB on the membrane surface, the
parameters for the B(OH)2 moiety of BZB were taken from Tafi et
al. [35] (see Text S1 for parameterization details.) Metadynamics
calculations were performed with a locally modified version of
NAMD2.6 [36]. Periodic boundary conditions were applied.
Simulations were performed in an isothermal-isobaric ensemble (1
atm, 300 K). The metadynamics simulation was carried out after
equilibration (see S.I). The free energy profile G(z) associated with
BZB translocation through the lipid bilayer was calculated along
the z-component of the distance vector joining the POPC
membrane and the BZB center of mass (z-dist hereafter, Fig. 2).
Following the suggestion of Laio et al. [37] we used the following
parameters for metadynamics (details in Text S1): the time interval
between the addition of two Gaussian functions t=100 fs, the
Gaussian height w=0.2 kJ/mol, the Gaussian width d=0.5 A ˚.
The error on the reconstructed G(z) has been shown to be
approximately determined by the ratio w/dt [37]: our choice is
consistent with ref. [24]. We inserted a rigid wall at z=633 A ˚ to
force the inhibitor inside the simulation box. The simulation was
stopped after two complete cycles, i.e. two up-down and two
down-up passages (15 ns). The reconstructed free energy profile
converged after 11 ns (see Fig. S3a for details). The reconstructed
G(z) was averaged over 5 free energy profiles after convergence,
obtaining ,G(z). [38]. The lipids are highly anisotropic,
therefore we also averaged the ,G(z). with respect to the z-dist
coordinate inside a four regions scheme [39] (see Fig. S3). The
permeability coefficient was calculated based on the estimated free
energy barrier [39,40] (see Text S1). Coordination numbers
between BZB oxygens (O1,O2) (see Fig. 1) and water oxygens,
(O(wat)), or the oxygens bound to the POPC phosphates, O(P-
popc), were calculated counting the number of water oxygens and
phosphate oxygens within a radius of 3.4 A ˚ from O1 (O2). This is
the distance between the first two peaks of the correlation function
of water oxygens. The dipole moment was calculated based on the
electrostatic term of the force field as in ref. [41].
Supporting Information
Figure S1 (A) Single-channel recording of a PC/
n-decane membrane in presence of purified OmpF of
E. coli K12. About 10 min after the formation of the membrane,
20 ng/ml of OmpF were added to the aqueous phase on both
sides of the membrane. The aqueous phase contained 1 M KCl.
The applied membrane potential was 20 mV, and the tempera-
ture was 20uC. (B) Same conditions as in A, but the aqueous phase
contained in addition 0.45 mM BZD. Note that the conductance
of the single-channel steps in B were by about 14% smaller than
those in A because of the interaction of the ion current through
OmpF with BZD.
(TIF)
Figure S2 Charge distribution of BZB [1] along with the
dipole moment m (D=2.85 Debye).
(TIF)
Figure S3 a) Free energy profile calculated every 1 ns.
The potential landscape is gradually filled (dotted lines). Since the
metadynamics converged (11 ns) we identified 5 different free
energy profiles (black lines). b) G(z) as a function of z-dist (A ˚). The
average (black line) of 5 independent profiles (Grey lines) is used to
calculate the mean value inside the four region scheme (red starts).
c) ball-and-sticks representation of a POPC molecule: P atoms are
colored in blue, C6 atoms are colored in cyan, N atoms are
colored in yellow. Bottom, right: snapshot of the equilibrated
POPC bilayer. Vertical lines indicate the boundaries between the
four regions defined in the text.
(TIF)
Text S1
(DOC)
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